Here comes a new post in our series inspired by Drug Hunter’s “Molecules of the Month”!
Below are two molecules that were recently highlighted by Drug Hunter!

1. ACT-777991 is an orally active, potent, and selective antagonist of the CXCR3 chemokine receptor. Such G protein-coupled receptor is expressed on adaptive and innate immune cells, like T-, B-, and NK cells. The interaction of CXCR3 with inducible chemokine ligands (CXCL9-11) activates a signaling cascade and leads to the migration of activated immune cells to sites of inflammation. The discovery of the ACT-777991 is a result of the CXCR3 antagonist program in the field of autoimmunity. This drug candidate showed efficacy and target engagement in a mouse model of acute lung inflammation and Type 1 Diabetes (T1D). Currently, ACT-777991 is in Phase 1 clinical trials for T1D with a promising safety profile.

You can find the analogs to this molecule here!

2. Zasocitinib (TAK-279/NDI-034858) is an oral, allosteric tyrosine kinase 2 (TYK2) inhibitor. TYK2 is a key intracellular enzyme which involved in immune signaling and inflammatory pathways. It plays a crucial role in innate and adaptive immune cells and serves as an essential component for maintaining proper immune responses. Zasocitinib was evaluated for the treatment of multiple autoimmune diseases. It has demonstrated exclusive functional selectivity and broad therapeutic margins in preclinical studies. Now zasocitinib demonstrates positive results in Phase IIb in treating patients with moderate-to-severe plaque psoriasis and active psoriatic arthritis.

You can find the analogs to this molecule here!

Use chem-space.com/search to find off-the-shelf and Make-on-Demand molecules of your interest!